NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Terran Orbital Corporation (NYSE:LLAP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/terran-orbital-corporation-lawsuit-submission-form?prid=108446&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call […]

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Methode Electronics, Inc. (NYSE:MEI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/methode-electronics-inc-lawsuit-submission-form?prid=108445&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your Stellantis N.V. (NYSE:STLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/stellantis-lawsuit-submission-form?prid=108444&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / If you suffered a loss on your iLearningEngines, Inc. (NASDAQ:AILE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ilearningengines-lawsuit-submission-form?prid=108443&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)

Nevada King Gold Corp. (TSXV: NKG) (OTC: NKGFF)(“Nevada King” or the “Company”) is pleased to announce the appointment of John Sclodnick as the Company’s President, effective November 1, 2024. Mr. Sclodnick will report to Collin Kettell, Nevada King’s Founder, CEO, and Director. https://mma.prnewswire.com/media/2529157/Nevada_King_Gold_Corp__NEVADA_KING_APPOINTS_JOHN_SCLODNICK_AS_PR.jpg Appointment of President: Mr. Sclodnick has worked in equity research for over

Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND) (OTCQB: MNDJF) is pleased to announce the appointment of John Jentz as an independent director of the Board of Directors (the “Board”), effective immediately. https://mma.prnewswire.com/media/2529135/Mandalay_Resources_Corporation_Mandalay_Resources_Announces_Appo.jpg Mr. Jentz brings over 20 years of experience in mining operations, board governance and M&A investment banking. Among his significant contributions

Jazz plans to submit supplemental New Drug Application in first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone

WhiteHorse Finance, Inc.(the “Company”) (Nasdaq: WHF) today announced that its board of directors has declared a special distribution of $0.245 per share, which will be payable on December 10, 2024 to stockholders of record as of October 31, 2024. Distributions are paid from taxable earnings and may include a return of capital and/or capital gains.

Alpha Metallurgical Resources, Inc. (NYSE:AMR) (“Alpha” or the “Company”), a leading U.S. supplier of metallurgical products for the steel industry, today announced preliminary sales volumes and realizations for the third quarter of 2024. https://mma.prnewswire.com/media/1429917/Alpha_Metallurgical_Resources_Logo.jpg “Our preliminary third quarter results reflect the market softness of the last few months, with revenues and shipment volumes both lower

Trevi Therapeutics, Inc.(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November. https://mma.prnewswire.com/media/1504281/Trevi_Therapeutics_Logo.jpg 3rd Chief Commercial Officer